Drug Trial Radar · NCT05468450
RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency
Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Jul 1, 2015
Primary completion
Aug 31, 2016
Study completion Aug 31, 2016
Sponsor
- Lead sponsor
- Societe Francaise de PhlebologieAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 21, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FOVELASS is a multicentre-RCT (11 centres) comparing ultrasound-guided-foam sclerotherapy (UGFS) and Endovenous Laser Ablation (EVLA) for treating SSV insufficiency, conducted by the French Society of Phlebology.
Conditions
- Varicose Veins of Lower Limb
Interventions
Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosantDrug
Direct injection Foam sclerotherapy
Endovenous Laser Ablation (EVLA)Device
EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absence of reflux in the treated SSV segmentTime frame: 3Assessed at years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.